Agents and Actions

, Volume 39, Supplement 1, pp C195–C197 | Cite as

Differential antagonism of platelet activating factor-induced neutrophilia and gastric hemorrhage in the rat

  • Theresa K. Thomas
  • Rosalind S. Chesonis
  • Diane Schmolze
  • Julia Symington
  • Margaret L. Harbison
  • Armin Walser
  • Peter C. Will
Tissue Damage

Abstract

Intravenous injection of platelet activating factor (PAF) in rats produced hypotension, neutrophilia, gastric congestion, and sloughing of the gastric epithelium. The congestion was quantified by measuring hemoglobin in the gastric mucosa. Other lesions were quantified by scores of gross pathology and histopathology. PAF-induced changes in neutrophil levels were prevented by pretreatment with the PAF-antagonist Ro24-4736, but not by the PAF-antagonist CV-3988. Both PAF antagonists reduced the hypotension, the amount of hemoglobin in the gastric mucosa, and the PAF-induced gastric pathology. These results suggest that PAF receptors involved in PAF-induced neutrophil mobilization respond differently from PAF receptors in the gastrointestinal and cardiovascular systems.

Keywords

Cardiovascular System Intravenous Injection Gastric Mucosa Activate Factor Platelet Activate 

References

  1. [1]
    S-B. Hwang,Specific receptors of platelet-activating factor, receptor heterogeneity, and signal transduction mechanisms. J. Lipid Mediator2, 123–158 (1990).Google Scholar
  2. [2]
    W. Hsueh, F. Gonzalez-Crussi, J. L. Arroyave, R. C. Anderson, M. L. Lee and W. J. Houlihan,Platelet activating factor-induced ischemic bowel necrosis: the effect of PAF antagonists. Eur. J. Pharmacol.123, 79–83 (1986).CrossRefPubMedGoogle Scholar
  3. [3]
    A. Dembinska-Kiec, B. A. Peskar, M. K. Muller and B. M. Peskar,The effects of platelet-activating factor on flow rate and eicosanoid releases in the isolated perfused rat gastric vascular bed. Prostaglandins37, 69–91 (1989).CrossRefPubMedGoogle Scholar
  4. [4]
    J. L. Wallace, G. Steel, B. J. R. Whittle, V. Lagente and B. Vargaftig,Evidence for platelet-activating factor as a mediator of endotoxin-induced gastrointestinal damage in the rat. Gastroenterology93, 765–773 (1987).PubMedGoogle Scholar
  5. [5]
    P. T. Bozza, P. M. R. Silva, H. C. Castro-Faria-Neto, M. A. Martins and R. S. B. Cordeiro,Increase in the rat blood leukocyte counts induced by PAF-acether is suppressed by general anesthesia. J. Leukoc. Biol.51, 146–150 (1992).PubMedGoogle Scholar
  6. [6]
    A. Etienne, F. Thonier and P. Braquet,Protective effect of the PAF-antagonist BN 52021 on several models of gastro-intestinal mucosal damage in rats. Int. J. Tissue React.11, 59–64 (1989).PubMedGoogle Scholar
  7. [7]
    A. Walser, T. Flynn, C. Mason, H. Crowley, C. Maresca, B. Yaremko and M. O'Donnell,Triazolobenzo and triazolothienodiazapines as potent antagonists of platelet-activating factor. J. Med. Chem.34, 1209–1221 (1991).CrossRefPubMedGoogle Scholar
  8. [8]
    P. Braquet, L. Touqui, T. Y. Shen and B. B. Vargaftig,Perspectives in platelet-activating factor research. Pharmacol. Rev.39, 97–145 (1987).PubMedGoogle Scholar

Copyright information

© Birkhäuser Verlag 1993

Authors and Affiliations

  • Theresa K. Thomas
    • 1
  • Rosalind S. Chesonis
    • 2
  • Diane Schmolze
    • 2
  • Julia Symington
    • 2
  • Margaret L. Harbison
    • 2
  • Armin Walser
    • 3
  • Peter C. Will
    • 1
  1. 1.Department of PharmacologyHoffmann-La Roche Inc.NutleyUSA
  2. 2.Department of Toxicology and PathologyHoffmann-La Roche Inc.NutleyUSA
  3. 3.Department of Medicinal ChemistryHoffmann-La Roche Inc.NutleyUSA

Personalised recommendations